News
Peptide research news
Recent reporting from peer-reviewed journals, clinical trial readouts, and reputable outlets. Curated by Perplexity, sources cited.
Rein Therapeutics to present inhaled LTI-03 data at ERS 2026
Rein Therapeutics said it will present a late-breaking poster on inhaled LTI-03 for idiopathic pulmonary fibrosis at ERS 2026. The poster is titled as a randomized dose-escalation study, indicating a clinical readout of a peptide-based candidate.
obesity-pipeline14 New Weight Loss Drugs
A roundup on new weight-loss drugs cites recent reporting that retatrutide led to the most weight loss among GLP-1-based treatments, while also noting notable side effects and ongoing pipeline interest.
trial readoutLow-dose GLP-1 use still produces weight loss, study finds
USA Today covered a new study suggesting low-dose GLP-1 starter regimens can still produce weight loss, with tirzepatide outperforming semaglutide but also showing notable side effects in some patients.
quality controlUther Peptide expands testing and batch transparency program
Uther Peptide announced expanded third-party testing and batch transparency for its research products. The post also referenced broader peptide-market coverage, but it is vendor-generated and not a peer-reviewed or mainstream news report.
Protagonist Therapeutics schedules investor conference appearances
Protagonist Therapeutics said its CEO will participate in upcoming investor conferences in September 2026. This is corporate news and does not report a clinical or research readout.
Metrix Bio aggregates peptide industry headlines
Metrix Bio aggregated peptide-related headlines, including testing updates and market items. The page is a directory-style aggregator rather than original reporting.
Protagonist Therapeutics to Participate in Two Investment Bank Conferences
Protagonist Therapeutics announced upcoming investor conference participation. The release is corporate news and does not itself report a new peptide clinical or research result.
manufacturer-newsNovo Nordisk launches Wegovy weight-loss pill in Germany
Novo Nordisk launched its Wegovy pill in Germany, a move highlighting the company’s push into oral obesity treatment as competition with Eli Lilly intensifies.
trial readoutGLP-1 obesity drugs work even at low starter doses
Reuters reported that people staying on low starter doses of GLP-1 obesity drugs still lost some weight, with average one-year losses of 5.5% on tirzepatide and 2.2% on semaglutide.